Effectiveness of Topical Cyclosporin A 0.1%, Diquafosol Tetrasodium 3%, and Their Combination, in Dry Eye Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness of Topical Cyclosporin A 0.1%, Diquafosol Tetrasodium 3%, and Their Combination, in Dry Eye Disease

Published:2022-12-01 Issue:10 Volume:38 Page:682-694
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Eom Youngsub¹²^ORCID,Song Jong Suk¹³^ORCID,Kim Hyo Myung¹⁴^ORCID

Affiliation:

1. Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea.

2. Department of Ophthalmology, Korea University Ansan Hospital, Gyeonggi-do, South Korea.

3. Department of Ophthalmology, Korea University Guro Hospital, Seoul, South Korea.

4. Department of Ophthalmology, Korea University Anam Hospital, Seoul, South Korea.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

https://www.liebertpub.com/doi/pdf/10.1089/jop.2022.0031

Reference53 articles.

1. TFOS DEWS II Tear Film Report

2. TFOS DEWS II Definition and Classification Report

3. Korean Guidelines for the Diagnosis and Management of Dry Eye: Development and Validation of Clinical Efficacy

4. TFOS DEWS II pathophysiology report

5. Dry Eye Disease: Impact on Quality of Life and Vision

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of human corneal epithelial organoids for ex vivo modelling dry eye disease;Cell Proliferation;2024-07-03

2. Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction;JAMA Ophthalmology;2024-07-01

3. Treatment of Dry Eye Disease (DED) in Asia: Strategies for Short Tear Film Breakup Time-Type DED;Pharmaceutics;2023-11-05

4. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial;BMC Ophthalmology;2023-08-03

5. Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials;Expert Opinion on Emerging Drugs;2023-04-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3